<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Albireo Pharma, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Albireo Pharma, Inc.

    Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Ron Cooper
    • FOUNDED
      2003
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Innovate Biopharmaceuticals, Inc.

    Innovate Biopharmaceuticals, Inc.

    Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company ...

    Innovate is a publicly traded (Nasdaq: INNT) cl...

    Filing Type:    PU
    GlycoMimetics, Inc.

    GlycoMimetics, Inc.

    At GlycoMimetics, we are committed to helping to make a difference in the lives of...

    At GlycoMimetics, we are committed to helping t...

    Filing Type:    PU
    Roche Holding Ltd

    Roche Holding Ltd

    Together, a potent new drug and a blood test to guide its use can be a life change...

    Together, a potent new drug and a blood test to...

    Filing Type:    PU
    Seelos Therapeutics, Inc.

    Seelos Therapeutics, Inc.

    Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a responsibly-driven company focused o...

    Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a r...

    Filing Type:    PU
    Surface Oncology, Inc.

    Surface Oncology, Inc.

    Surface Oncology is an immuno-oncology company on a mission to break through and d...

    Surface Oncology is an immuno-oncology company ...

    Filing Type:    PU
    Shionogi & Co. Ltd.

    Shionogi & Co. Ltd.

    Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, an...

    Shionogi & Co., Ltd. engages in the research, d...

    Filing Type:    PU
    Tiziana Life Sciences plc

    Tiziana Life Sciences plc

    Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...

    Tiziana Life Sciences is a dual-listed (NASDAQ:...

    Filing Type:    PU
    Galmed Pharmaceuticals Ltd.

    Galmed Pharmaceuticals Ltd.

    Galmed is a clinical-stage biopharmaceutical company focused on the development of...

    Galmed is a clinical-stage biopharmaceutical co...

    Filing Type:    PU
    Dicerna Pharmaceuticals, Inc.

    Dicerna Pharmaceuticals, Inc.

    Dicerna is a biopharmaceutical company focused on the discovery and development of...

    Dicerna is a biopharmaceutical company focused ...

    Filing Type:    PU
    Protagonist Therapeutics, Inc.

    Protagonist Therapeutics, Inc.

    Protagonist Therapeutics is a clinical stage biopharmaceutical company that utiliz...

    Protagonist Therapeutics is a clinical stage bi...

    Filing Type:    PU
    Evoke Pharma, Inc.

    Evoke Pharma, Inc.

    Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused pr...

    Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialt...

    Filing Type:    PU
    Redhill Biopharma Ltd.

    Redhill Biopharma Ltd.

    RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a special...

    RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.